Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 5
Panelists discuss how isatuximab-containing quadruplet regimens offer clinical benefit in patients with 1q gain or amplification, though its advantage appears to reflect a class effect among CD38-targeting agents.
Targeting 1q Gain and Managing High-Risk Genetic Features
Studies exploring the benefit of anti-CD38 monoclonal antibodies in patients with 1q gain/amplification show that these regimens offer improved progression-free survival even in genetically defined high-risk subgroups. The heterogeneity within 1q abnormalities underscores the need for refined risk definitions.
Findings also reinforce that the addition of CD38-targeting agents improves outcomes across cytogenetic subsets. However, in true ultra–high-risk patients, such as those with multiple adverse genetic markers, further therapeutic innovation is required.
These data point to the growing importance of personalized medicine in multiple myeloma, where treatment is tailored based not only on eligibility and performance status but also on detailed cytogenetic and molecular profiling.